bluebird bio Inc. (BLUE)

206.05
NASDAQ : Health Technology
Prev Close 201.20
Day Low/High 199.65 / 206.35
52 Wk Low/High 74.45 / 222.03
Avg Volume 928.10K
Exchange NASDAQ
Shares Outstanding 49.03M
Market Cap 10.17B
EPS -7.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio To Present At LEERINK Partners Global Healthcare Conference

Bluebird Bio To Present At LEERINK Partners Global Healthcare Conference

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Bluebird Bio Announces Closing Of Over-Allotment Option In Public Offering

Bluebird Bio Announces Closing Of Over-Allotment Option In Public Offering

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Bluebird Bio To Present At Investor Conferences In January

Bluebird Bio To Present At Investor Conferences In January

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an...

Bluebird Bio Stock Soars After Company Details Promising Cancer Treatment

Bluebird Bio Stock Soars After Company Details Promising Cancer Treatment

The Cambridge, Mass.-based firm's presentations at the American Society of Hematology's annual meeting sent its stock soaring on Monday.

Dow and S&P 500 Post New Records as Concerns Ebb Over New York Explosion

Dow and S&P 500 Post New Records as Concerns Ebb Over New York Explosion

The Dow, S&P 500 and Nasdaq all finished higher on Monday.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an...

Video: Jim Cramer on Bitcoin, Bluebird Bio and This Weeks Fed Meeting

Video: Jim Cramer on Bitcoin, Bluebird Bio and This Weeks Fed Meeting

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending topics including bitcoin futures, Bluebird Bio and what to expect from this week's Federal Reserve meeting.

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.

Stocks Trade Higher Following Explosion at New York's Port Authority

Stocks Trade Higher Following Explosion at New York's Port Authority

Stocks turn higher on Monday.

Despite Bluebird Bio's 17% Rally, Another 55% Surge Could Be Coming

Despite Bluebird Bio's 17% Rally, Another 55% Surge Could Be Coming

Shares of Bluebird Bio are up almost 20% in early Monday trading, but another 50% surge could be coming, according to Goldman Sachs.

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

Bluebird Bio Presents Updated Data From HGB-205 Study Of LentiGlobinTM Gene Therapy In Patients With Severe Sickle Cell Disease And Transfusion-Dependent ß-Thalassemia At American Society Of Hematology Annual Meeting

Bluebird Bio Presents Updated Data From HGB-205 Study Of LentiGlobinTM Gene Therapy In Patients With Severe Sickle Cell Disease And Transfusion-Dependent ß-Thalassemia At American Society Of Hematology Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced updated...

Bluebird Bio Announces Updated Clinical Results From Ongoing Phase 1 Multicenter Study Of LentiGlobin™ Gene Therapy In Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

Bluebird Bio Announces Updated Clinical Results From Ongoing Phase 1 Multicenter Study Of LentiGlobin™ Gene Therapy In Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced...

Bluebird Bio Presents New Data From Clinical Studies Of LentiGlobin™ Gene Therapy In Transfusion-Dependent ß-Thalassemia At American Society Of Hematology Annual Meeting

Bluebird Bio Presents New Data From Clinical Studies Of LentiGlobin™ Gene Therapy In Transfusion-Dependent ß-Thalassemia At American Society Of Hematology Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced...

Celgene Corporation And Bluebird Bio Announce Updated Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Celgene Corporation And Bluebird Bio Announce Updated Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen...

Bluebird Bio And TC BioPharm Announce Strategic Collaboration To Research And Develop Gamma Delta CAR T Cell Product Candidates For Cancer Immunotherapy

Bluebird Bio And TC BioPharm Announce Strategic Collaboration To Research And Develop Gamma Delta CAR T Cell Product Candidates For Cancer Immunotherapy

bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd.

Bluebird Bio Acquires Manufacturing Facility In North Carolina And Executes Multiple Global Supply Agreements To Enhance Ability To Deliver Gene Therapies To Patients

Bluebird Bio Acquires Manufacturing Facility In North Carolina And Executes Multiple Global Supply Agreements To Enhance Ability To Deliver Gene Therapies To Patients

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today...

Celgene Corporation And Bluebird Bio Announce Bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation From FDA And Prime Eligibility From EMA For Relapsed And Refractory Multiple Myeloma

Celgene Corporation And Bluebird Bio Announce Bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation From FDA And Prime Eligibility From EMA For Relapsed And Refractory Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated...

Bluebird Bio Announces First Patient Treated In Northstar-3 (HGB-212), Phase 3 Study Of LentiGlobin™ In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And ß0/ß0 Genotype

Bluebird Bio Announces First Patient Treated In Northstar-3 (HGB-212), Phase 3 Study Of LentiGlobin™ In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And ß0/ß0 Genotype

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced...

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

There are some signs of selling into the strength especially in technology names.

Bluebird Bio To Present New Data From Clinical Studies Of LentiGlobinTM Gene Therapy In Transfusion-Dependent ß-Thalassemia And Severe Sickle Cell Disease And Bb2121 In Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Bluebird Bio To Present New Data From Clinical Studies Of LentiGlobinTM Gene Therapy In Transfusion-Dependent ß-Thalassemia And Severe Sickle Cell Disease And Bb2121 In Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Reports Third Quarter 2017 Financial Results And Recent Operational Progress

Bluebird Bio Reports Third Quarter 2017 Financial Results And Recent Operational Progress

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business...

TheStreet Quant Rating: D+ (Sell)